[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polycystic-kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polycystic-kidney-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,72,94,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100541114","well-formulated-ketogenic-diet-polycystic-kidney-disease-100541114",false,"NCT06325644","Well-Formulated Ketogenic Diet Polycystic Kidney Disease","Feasibility and Efficacy of a Well-Formulated Ketogenic Diet in Delaying Progression of Polycystic Kidney Disease in Patients at Risk for Rapid Progression","Inclusion Criteria:\n\n* Age 18-65 years old\n* Diagnosis of ADPKD by imaging and\u002For genetic testing\n* GFR ≥ 25 mg\u002Fdl\n* Patients at risk for rapid progression of ADPKD: Mayo Class 1C-1E along with any other high risk features including early decline in GFR, hypertension onset ≤ 35 years of age, urologic events ≤ 35 years of age, PKD 1 truncating mutation and PROPKD score of 4 or higher as determined by the treating physician\n* No changes of medications within the last three months.\n* Able to comply with dietary intervention\n* Ability to sign informed consent\n\nExclusion Criteria:\n\n* Patients currently being treated with Tolvaptan\n* Diagnosed with diabetes.\n* Pregnancy\n* Contraindications to MRI\n* Ketogenic diet within the last three months\n* Severe kidney disease with GFR \\\u003C 25 mg\u002Fdl\n* Unable to purchase food for the diet intervention\n* Gastrointestinal disorders that will interfere with diet intervention\n* Chronic alcohol or drug abuse","ALL","18 Years","65 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective study to determine ketogenic diet effect on htTKV, GFR, microalbuminuria. This is a single-center study of 20 patients with ADPKD and deemed high risk for progression to ESRD. This determined by combination of features of ADPKD and htTKV as assessed by prior computed tomography (CT) or MRI. Patients will be recruited from the Polycystic Kidney Disease (PKD) Clinic at Ohio State University Wexner Medical Center. Enrolled patients will have MRI for htTKV, urinary studies, blood tests at baseline, 6 months, and 52 weeks. Blood for GFR will be assessed three times over the course of the study including baseline, 6 months, and 1 year. Participants will follow ketogenic diet for 52 weeks. Investigatory diet team will manage the ketogenic diet.",[27],"Polycystic Kidney Disease","RECRUITING","2026-05-12",{"date":31,"type":32},"2026-05-14","ACTUAL",{"date":34,"type":32},"2024-06-01",{"date":36,"type":21},"2027-04-01",{"name":38,"class":39},"Ohio State University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100280926","early-pkd-observational-cohort-study-100280926","NCT02936791","Early PKD Observational Cohort Study","EPOC","Inclusion Criteria:\n\n* Inclusion for early stage autosomal dominant polycystic kidney disease (ADPKD):\n\n  * Family history of PKD\n  * All races and ethnic groups\n  * Glomerular filtration rate (GFR) \\>80 ml\u002Fmin per 1.73 m2\n* Inclusion for Healthy Volunteers:\n\n  * Male or female with no family history of kidney disease\n  * All races and ethnic groups\n  * Normal GFR\n\nExclusion Criteria:\n\n* Non-insulin or insulin-dependent diabetes mellitus\n* Systemic illness (i.e.systemic lupus erythematosus, vasculitis)\n* Unable to provide written informed consent\n* Unavailable for magnetic resonance imaging (MRI) and blood\u002Furine collection",true,"4 Years","35 Years",{"count":52,"type":21},250,"10 Years","OBSERVATIONAL","This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested.",[27],[58,59,60,61,62],"autosomal dominant polycystic kidney disease","ADPKD","PKD biomarkers","Kidney Institute","University of Kansas Medical Center","2026-04-23",{"date":65,"type":32},"2026-04-27",{"date":67,"type":32},"2016-04",{"date":69,"type":21},"2031-06",{"name":62,"class":39},3,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":40},"100117250","polycystic-kidney-disease-data-repository-100117250","NCT00792155","Polycystic Kidney Disease Data Repository","Autosomal Dominant Polycystic Kidney Disease Data Repository","Inclusion Criteria:\n\n* Any person, age 18 or older, with previously diagnosed ADPKD is eligible to participate.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.",{"count":80,"type":21},1000,"Autosomal dominant polycystic kidney disease (PKD) is the most common inherited kidney disease, affecting more than 400,000 people in the U.S. and 5 million people worldwide. PKD is the 4th most common cause of kidney failure requiring dialysis and\u002For transplantation. Over half of all PKD patients develop kidney failure by age 60 years, although age of onset of kidney disease varies widely, even among members of the same family.\n\nDespite the fact this is a relatively common problem, relatively few patients have been studied for a sufficient period of time to fully understand how patients are affected over the course of their lifetime. The reason for creating this repository is to collect information about PKD so that the investigators may fully understand its complications, including high blood pressure, heart attack, and stroke. This information may also aid in the development of improved treatment strategies.",[27],[84],"PKD","2025-11-07",{"date":87,"type":32},"2025-11-12",{"date":89,"type":4},"2002-11",{"date":91,"type":21},"2030-12",{"name":93,"class":39},"The Rogosin Institute",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":103,"studyType":54,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":40},"100199496","pkd-clinical-and-translational-core-study-100199496","NCT01873235","PKD Clinical and Translational Core Study","The Baltimore Polycystic Kidney Disease Clinical and Translational Core Study","Inclusion criteria:\n\n* Age 18 and older\n* ADPKD confirmed by genetic testing or ultrasound criteria using modified Ravine criteria: with family history:several cysts per kidney (3 by sonography, 5 if by computerized tomography or MRI)without family history: 10 cysts (by any radiologic method) per kidney and exclusion of other cystic kidney diseases\n* Ability to provide written informed consent prior to initiation of any study procedures and the ability in the opinion of the investigator to comply with all requirements of the study\n* Glomerular Filtration Rate (GFR) greater than 15ml\u002Fmin\u002F1.73m2\n\nExclusion Criteria:\n\n* End Stage Renal Disease or presently on dialysis or a prior kidney transplant\n\n  --Pregnant, lactating, or intention to get pregnant in next 6 weeks\n* Another systemic disease such as cancer or lupus\n* Life expectancy less than 2 years\n* Current participation in a drug treatment trial\n* Non English speaking\n* Uncontrolled diabetes A1C 7.0 or more within 6 months of study visit; and\u002For on more than one oral hypoglycemic agent\n* Diabetic nephropathy",{"count":102,"type":21},350,"8 Years","Advances in our understanding of the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) have opened up possibilities of new therapies to prevent disease progression. High quality clinical investigations in patients with ADPKD, however, pose significant challenges to investigators including limited access to patients with ADPKD,insufficient guidance by experienced investigators and lack of resources to conduct these studies.\n\nThe Polycystic Kidney Disease Research Clinical and Translational Core (P30) aims to establish an infrastructure that will assist investigators in designing and conducting highest quality clinical and translational research focused on a diverse group of patients with ADPKD.\n\nObjective 1: To establish a Mid-Atlantic cohort of ADPKD patients (N=350) with baseline clinical phenotyping performed at the General Clinical Research Unit of the University of Maryland School of Medicine.\n\nObjective 2: To establish a state-of-the-art biobank of specimens from the ADPKD cohort including serum, plasma,urine and DNA.\n\nObjective 3: To develop a collaborative network of physicians and practices in the Mid-Atlantic region who will contribute to the ADPKD cohort and will be willing to refer patients for future studies and trials.\n\nObjective 4: To establish a web-based registry of ADPKD patients in the Mid-Atlantic area.",[27],"2025-09-08",{"date":108,"type":32},"2025-09-11",{"date":110,"type":32},"2013-03",{"date":112,"type":21},"2030-06",{"name":114,"class":39},"University of Maryland, Baltimore",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":121,"minAge":4,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":135,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":40},"100572051","amnioinfusion-for-fetal-renal-failure-100572051","NCT06728228","Amnioinfusion for Fetal Renal Failure","Inclusion criteria:\n\n1. Confirmed anhydramnios before 22 weeks GA for patients with FRF.\n2. Consent is signed and first therapeutic amnioinfusion can and does occur before 28 weeks and 6\u002F7 days GA.\n3. Confirmation that the expectant mother understands her options for management of the pregnancy.\n4. Age ≥18 years of age.\n5. Willingness to be followed by the Fetal Care Center at Dallas and deliver at Medical City Dallas.\n6. Willingness for postnatal care to be performed at Medical City Dallas Hospital\u002Fthe Fetal Care Center until maternal discharge.\n7. Consults with Pediatric Nephrology, Neonatology, Transplant Surgery, Pediatric surgery, Maternal-Fetal Medicine Specialist, and a Genetic Counselor.\n\nExclusion criteria:\n\n1. Cervix less than 2.5 cm in length.\n2. No fatal findings on Karyotype (e.g trisomy 13, or 18) or Microarray fatal findings excluding those that are related to pulmonary hypoplasia due to fetal renal failure (e.g. Meckel-Gruber, PCKD).\n3. Other significant congenital anomalies in the fetus.\n4. Evidence of chorioamnionitis or abruptio placentae.\n5. Evidence of rupture of membranes or chorionic-amniotic separation.\n6. Evidence of preterm labor.\n7. Multiple gestation.\n8. Severe maternal medical condition in pregnancy.\n9. Clinically diagnosed maternal depression, psychoses, or anxiety that are refractory to treatment.\n10. Technical limitations precluding amnioinfusion.","FEMALE",{"count":123,"type":21},35,[24],"The goal of this clinical trial is to learn if serial amnioinfusions can improve the chances of survival for fetuses with severe kidney problems that cause low amniotic fluid (anhydramnios). Low amniotic fluid can affect lung development and may lead to serious health issues for the fetus. The main questions this study aims to answer are:\n\n* Can serial amnioinfusion increase the chances of survival for these fetuses?\n* Does this procedure improve chances of survival until dialysis and\u002For kidney transplant?\n\nParticipants will:\n\n* Receive regular amnioinfusions, which is a procedure that adds fluid to the amniotic cavity.\n* Undergo monitoring to check the effects on the fetus and mother.\n\nThis study will help researchers understand if amnioinfusion is a useful treatment for fetal kidney problems and may provide valuable information for similar cases in the future.",[127,27,128,129,130,131,132,133,134],"Multicystic Dysplastic Kidney","Fetal Renal Anomaly","Anhydramnios","Potter Syndrome","Lung Hypoplasia","Multicystic Renal Dysplasia, Bilateral","Lower Urinary Tract Obstructive Syndrome","Bilateral Renal Agenesis",[136,137,138,139],"Fetal Renal Failure","Kidney Disease","MCDK","PCKD","2024-12-18",{"date":142,"type":32},"2024-12-20",{"date":144,"type":32},"2024-12-05",{"date":146,"type":21},"2026-11-15",{"name":148,"class":149},"Fetal Care Center, PLLC","INDUSTRY"]